
OncoZenge Q1 - Pieces falling into place

Redeye provides a research update following the Q1 report published by OncoZenge earlier today. The company manages to maintain a low OPEX and cash burn as the prepares for the upcoming phase III trial. Bolstered by a binding partnership agreement with Molteni, an NDRC approval of the financing agreement with Yangtian Pharma and a new licensing agreement with Avernus Pharma, we argue that the pieces are falling into place for the company.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

OncoZenge Q1 - Pieces falling into place